Are you referring to the recent preferred share offering which is convertible into shares at .095? What shares are they selling? The common shares haven't been registered yet. The Company is trying to get authorization for an increase of the common stock. Even if they had been registered, would Aquarius convert at .095 and then sell at .06??????
You are a liar ...... never said any such thing.
Ask you boiler room master for more believable material.
I just bought some today.
Documented facts vs hype.
Fall for the hype and it will kill you.
The timing couldn't be more perfect. I've been looking to buy a low priced stock after the run up here.
If I stay here much longer, I'll give back all my profits.
Monthly expenses are $400K - so about $5M annually.
The machines sell for about $20K. The margins are slim until production ramps up.
The disposable guides have a profit margin of about 90%.
So it depends on the allocation of sales.
Once lots of units are placed. profits will roll in from the high margin disposable guides.
The international market is so large that the US can wait.
Biotechs who receive CRLs burn cash until resubmission and approval.
GTHP, on the other hand, is launching their product internationally.
It would have been spread too thin trying to market in the US too.
The drop in the stock price was an overreaction.
The international market is where the action is.
The US market would have been a side show and a distraction at this time.
100,000 X $20,000 each = $2,000,000
Is the sales price about $20K per machine?.
Plus the 100,000 diposables at $15 each? = $1,500,000.
Gene should achieve the $3M projection for this year.
If Nigeria and Kenya kick in later this year ..........................
International markets is where the action is.
GTHP is approved there and selling product.
The FDA is a minor inconvenience, a bump in the road.
Buying opportunity - the international markets are opening up and the market cap is a low $17M.
If I didn't hold so many shares already, I'd be buying now.